Infections in hemodialysis: A concise review. Part II: Blood transmitted viral infections

Hippokratia

Volumn 15, Issue 2, 2011, Pages 120-126

  Eleftheriadis, Theodoros ^a   Liakopoulos, V ^a   Leivaditis, K ^a   Antoniadi, G ^a   Stefanidis, I ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

Hemodialysis; Hepatitis B virus; Hepatitis C virus; Human immunodeficiency virus; Infection; Review

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS C ANTIBODY; LAMIVUDINE; TELBIVUDINE; VIRUS RNA;

ADAPTIVE IMMUNITY; ANEMIA; ANTIVIRAL RESISTANCE; BACTERIAL INFECTION; BACTERIAL TRANSMISSION; CACHEXIA; DRUG WITHDRAWAL; HEALTH CARE PERSONNEL; HEMODIALYSIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION SENSITIVITY; INNATE IMMUNITY; KIDNEY FAILURE; LIVER BIOPSY; PATIENT SAFETY; POLYMERASE CHAIN REACTION; REVIEW; RISK BENEFIT ANALYSIS; RNA ANALYSIS; VIRUS INFECTION; VIRUS TRANSMISSION;

EID: 79955445765     PISSN: 11084189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (116)

1. Lewis SL, Van Epps DE, Chenoweth DE. Alterations in chemotactic factor-induced responses of neutrophils and monocytes from chronic dialysis patients. Clin Nephrol. 1988; 30: 63-72.
2. Muniz-Junqueira MI, Braga Lopes C, Magalhaes CA, Schleicher CC, Veiga JP. Acute and chronic influence of hemodialysis according to the membrane used on phagocytic function of neutrophils and monocytes and pro-inflammatory cytokines production in chronic renal failure patients. Life Sci. 2005; 77: 3141-3155.
3. Eleftheriadis T, Kartsios C, Yiannaki E, Kazila P, Antoniadi G, Liakopoulos V, et al. Chronic inflammation and CD16+ natural killer cell zeta-chain downregulation in hemodialysis patients. Blood Purif. 2008; 26: 317-321.
4. Eleftheriadis T, Papazisis K, Kortsaris A, Vayonas G, Voyatzi S, Vargemezis V. Impaired T cell proliferation and zeta chain phosphorylation after stimulation with staphylococcal enterotoxin-B in hemodialysis patients. Nephron Clin Pract. 2004; 96: c15-20.
5. Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I. Disturbances of acquired immunity in hemodialysis patients. Semin Dial. 2007; 20: 440-451.
6. Eleftheriadis T, Kartsios C, Yiannaki E, Kazila P, Antoniadi G, Liakopoulos V, et al. Chronic inflammation and T cell zeta-chain downregulation in hemodialysis patients. Am J Nephrol. 2008; 28: 152-157.
7. Morbidity & Mortality. American journal of kidney diseases: the official journal of the National Kidney Foundation; 55: S269-S280.
8. Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int. 2000; 58: 1758-1764.
9. Foley RN, Guo H, Snyder JJ, Gilbertson DT, Collins AJ. Septicemia in the United States dialysis population, 1991 to 1999. J Am Soc Nephrol. 2004; 15: 1038-1045.
10. Beathard GA, Urbanes A. Infection associated with tunneled hemodialysis catheters. Semin Dial. 2008; 21: 528-538.
11. Kausz A, Pahari D. The value of vaccination in chronic kidney disease. Semin Dial. 2004; 17: 9-11.
12. Hussein MM, Mooij JM, Roujouleh H. Tuberculosis and chronic renal disease. Semin Dial. 2003; 16: 38-44.
13. Fabrizi F, Messa P, Martin P. Hepatitis B virus infection and the dialysis patient. Semin Dial. 2008; 21: 440-446.
14. Fabrizi F, Lunghi G, Ganeshan SV, Martin P, Messa P. Hepatitis C virus infection and the dialysis patient. Semin Dial. 2007; 20: 416-422.
15. Rao TK. Human immunodeficiency virus infection in end-stage renal disease patients. Semin Dial. 2003; 16: 233-244.
16. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004; 11: 97-107.
17. Szmuness W, Prince AM, Grady GF, Mann MK, Levine RW, Friedman EA, et al. Hepatitis B infection. A point-prevalence study in 15 US hemodialysis centers. JAMA. 1974; 227: 901-906.
18. London WT, Drew JS, Lustbader ED, Werner BG, Blumberg BS. Host responses to hepatitis B infection in patients in a chronic hemodialysis unit. Kidney Int. 1977; 12: 51-58.
19. Sampliner RE. The duration of hepatitis B surface antigenemia. Arch Intern Med. 1979; 139: 145-146.
20. Harnett JD, Parfrey PS, Kennedy M, Zeldis JB, Steinman TI, Guttmann RD. The long-term outcome of hepatitis B infection in hemodialysis patients. Am J Kidney Dis. 1988; 11: 210-213.
21. Josselson J, Kyser BA, Weir MR, Sadler JH. Hepatitis B surface antigenemia in a chronic hemodialysis program: lack of influence on morbidity and mortality. Am J Kidney Dis. 1987; 9: 456-461.
22. Friedlaender MM, Kaspa RT, Rubinger D, Silver J, Popovtzer MM. Renal transplantation is not contraindicated in asymptomatic carriers of hepatitis B surface antigen. Am J Kidney Dis. 1989; 14: 204-210.
23. Pirson Y, Alexandre GP, Ypersele C. Long-term effect of hbs antigenemia on patient survival after renal transplantation. N Engl J Med. 1977; 296: 194-196.
24. Weir MR, Kirkman RL, Strom TB, Tilney NL. Liver disease in recipients of long-functioning renal allografts. Kidney Int. 1985; 28: 839-844.
25. Parfrey PS, Forbes RD, Hutchinson TA, Kenick S, Farge D, Dauphinee WD, et al. The impact of renal transplantation on the course of hepatitis B liver disease. Transplantation. 1985; 39: 610-615.
26. Chan TM, Fang GX, Tang CS, Cheng IK, Lai KN, Ho SK. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology. 2002; 36: 1246-1252.
27. Fabrizi F, Martin P, Dixit V, Kanwal F, Dulai G. HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant. 2005; 5: 2913-2921.
28. Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005; 54: 1-31.
29. Minuk GY, Sun DF, Greenberg R, Zhang M, Hawkins K, Uhanova J, et al. Occult hepatitis B virus infection in a North American adult hemodialysis patient population. Hepatology. 2004; 40: 1072-1077.
30. Hui CK, Sun J, Au WY, Lie AK, Yueng YH, Zhang HY, et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol. 2005; 42: 813-819.
31. Yasuda K, Okuda K, Endo N, Ishiwatari Y, Ikeda R, Hayashi H, et al. Hypoaminotransferasemia in patients undergoing longterm hemodialysis: clinical and biochemical appraisal. Gastroenterology. 1995; 109: 1295-1300.
32. Blum HE. Hepatitis B virus: significance of naturally occurring mutants. Intervirology. 1993; 35: 40-50.
33. Ozdogan M, Ozgur O, Gur G, Boyacioglu S, Ozderin Y, Demirhan B, et al. Histopathological impacts of hepatitis virus infection in hemodialysis patients: should liver biopsy be performed before renal transplantation? Artif Organs. 1997; 21: 355-358.
34. Degott C, Degos F, Jungers P, Naret C, Courouce AM, Potet F, et al. Relationship between liver histopathological changes and HBsAg in 111 patients treated by long-term hemodialysis. Liver. 1983; 3: 377-384.
35. Gane E, Pilmore H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation. 2002; 74: 427-437.
36. Duarte R, Huraib S, Said R, Abdel-Khadir A, Sullivan S, Chaballout A, et al. Interferon-alpha facilitates renal transplantation in hemodialysis patients with chronic viral hepatitis. Am J Kidney Dis. 1995; 25: 40-45.
37. Chan TM, Wu PC, Lau JY, Lok AS, Lai CL, Cheng IK. Interferon treatment for hepatitis C virus infection in patients on haemodialysis. Nephrol Dial Transplant. 1997; 12: 1414-1419.
38. Campistol JM, Esforzado N, Martinez J, Rosello L, Veciana L, Modol J, et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre-and post-renal transplantation assessment. Nephrol Dial Transplant. 1999; 14: 2704-2709.
39. Boyacioglu S, Gur G, Gursoy M, Ozdemir N. Lamivudine in renal transplant candidates with chronic hepatitis B infection. Transplant Proc. 2002; 34: 2131-2132.
40. Schmilovitz-Weiss H, Melzer E, Tur-Kaspa R, Ben-Ari Z. Excellent outcome of Lamivudine treatment in patients with chronic renal failure and hepatitis B virus infection. J Clin Gastroenterol. 2003; 37: 64-67.
41. Lapinski TW, Flisiak R, Jaroszewicz J, Michalewicz M, Kowalczuk O. Efficiency and safety of lamivudine therapy in patients with chronic HBV infection, dialysis or after kidney transplantation. World J Gastroenterol. 2005; 11: 400-402.
42. Kletzmayr J, Watschinger B, Muller C, Demetriou D, Puchhammer-Stockl E, Ferenci P, et al. Twelve months of lamivudine treatment for chronic hepatitis B virus infection in renal transplant recipients. Transplantation. 2000; 70: 1404-1407.
43. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology. 2000; 119: 172-180.
44. Fontaine H, Thiers V, Chretien Y, Zylberberg H, Poupon RE, Brechot C, et al. HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. Transplantation. 2000; 69: 2090-2094.
45. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007; 357: 2576-2588.
46. Bergervoet PW, van Riessen N, Sebens FW, van der Zwet WC. Application of the forensic Luminol for blood in infection control. J Hosp Infect. 2008; 68: 329-333.
47. Tokars JI, Alter MJ, Miller E, Moyer LA, Favero MS. National surveillance of dialysis associated diseases in the United States--1994. ASAIO J. 1997; 43: 108-119.
48. Tokars JI, Finelli L, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2001. Semin Dial. 2004; 17: 310-319.
49. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep. 2001; 50: 1-43.
50. Bond WW, Favero MS, Petersen NJ, Gravelle CR, Ebert JW, Maynard JE. Survival of hepatitis B virus after drying and storage for one week. Lancet. 1981; 1: 550-551.
51. Favero MS, Bond WW, Petersen NJ, Berquist KR, Maynard JE. Detection methods for study of the stability of hepatitis B antigen on surfaces. J Infect Dis. 1974; 129: 210-212.
52. Kamili S, Krawczynski K, McCaustland K, Li X, Alter MJ. Infectivity of hepatitis C virus in plasma after drying and storing at room temperature. Infect Control Hosp Epidemiol. 2007; 28: 519-524.
53. Beltrami EM, Williams IT, Shapiro CN, Chamberland ME. Risk and management of blood-borne infections in health care workers. Clin Microbiol Rev. 2000; 13: 385-407.
54. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. MMWR Recomm Rep. 2001; 50: 1-52.
55. Miller ER, Alter MJ, Tokars JI. Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am J Kidney Dis. 1999; 33: 356-360.
56. Eleftheriadis T, Liakopoulos V, Antoniadi G, Stefanidis I, Galaktidou G. Indoleamine 2, 3-dioxygenase is increased in hemodialysis patients and affects immune response to hepatitis B vaccination. Vaccine. 2011; 29: 2242-2247.
57. Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmuness W. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med. 1984; 311: 496-501.
58. Buti M, Viladomiu L, Jardi R, Olmos A, Rodriguez JA, Bartolome J, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients. Am J Nephrol. 1992; 12: 144-147.
59. Bruguera M, Rodicio JL, Alcazar JM, Oliver A, Del Rio G, Esteban-Mur R. Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients. Vaccine 1990; 8 Suppl: S47-9; discussion S60-62.
60. Dinits-Pensy M, Forrest GN, Cross AS, Hise MK. The use of vaccines in adult patients with renal disease. Am J Kidney Dis. 2005; 46: 997-1011.
61. Charest AF, Grand'Maison A, McDougall J, Goldstein MB. Evolution of naturally acquired hepatitis B immunity in the long-term hemodialysis population. Am J Kidney Dis. 2003; 42: 1193-1199.
62. Tsouchnikas I, Dounousi E, Xanthopoulou K, Papakonstantinou S, Thomoglou V, Tsakiris D. Loss of hepatitis B immunity in hemodialysis patients acquired either naturally or after vaccination. Clin Nephrol. 2007; 68: 228-234.
63. DaRoza G, Loewen A, Djurdjev O, Love J, Kempston C, Burnett S, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis. 2003; 42: 1184-1192.
64. Kong NC, Beran J, Kee SA, Miguel JL, Sanchez C, Bayas JM, et al. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int. 2008; 73: 856-862.
65. Yen T, Keeffe EB, Ahmed A. The epidemiology of hepatitis C virus infection. J Clin Gastroenterol. 2003; 36: 47-53.
66. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Metaanalysis: Effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther. 2004; 20: 1271-1277.
67. Fabrizi F, Lunghi G, Raffaele L, Guarnori I, Bacchini G, Corti M, et al. Serologic survey for control of hepatitis C in haemodialysis patients: third-generation assays and analysis of costs. Nephrol Dial Transplant. 1997; 12: 298-303.
68. Fehr T, Ambuhl PM. Chronic hepatitis virus infections in patients on renal replacement therapy. Nephrol Dial Transplant. 2004; 19: 1049-1053.
69. Fabrizi F, Poordad FF, Martin P. Diagnostic workup of hepatitis C and the patient on maintenance dialysis. Int J Artif Organs. 2001; 24: 843-852.
70. Tanaka E, Ohue C, Aoyagi K, Yamaguchi K, Yagi S, Kiyosawa K, et al. Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA. Hepatology. 2000; 32: 388-393.
71. Aoyagi K, Ohue C, Iida K, Kimura T, Tanaka E, Kiyosawa K, et al. Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J Clin Microbiol. 1999; 37: 1802-1808.
72. Kurtz JB, Boxall E, Qusir N, Shirley J, Coleman D, Chandler C. The diagnostic significance of an assay for 'total' hepatitis C core antigen. J Virol Methods. 2001; 96: 127-132.
73. Galan F, Perez-Gracia MT, Lozano A, Benavides B, Fernandez-Ruiz E, Rodriguez-Iglesias MA. A 3-year follow-up of HCVRNA viraemia in haemodialysis patients. Nephrol Dial Transplant. 1998; 13: 1211-1214.
74. Barril G, Castillo I, Arenas MD, Espinosa M, Garcia-Valdecasas J, Garcia-Fernandez N, et al. Occult hepatitis C virus infection among hemodialysis patients. J Am Soc Nephrol. 2008; 19: 2288-2292.
75. Umlauft F, Gruenewald K, Weiss G, Kessler H, Urbanek M, Haun M, et al. Patterns of hepatitis C viremia in patients receiving hemodialysis. Am J Gastroenterol. 1997; 92: 73-78.
76. al Meshari K, al Ahdal M, Alfurayh O, Ali A, De Vol E, Kessie G. New insights into hepatitis C virus infection of hemodialysis patients: the implications. Am J Kidney Dis. 1995; 25: 572-578.
77. Kalantar-Zadeh K, Miller LG, Daar ES. Diagnostic discordance for hepatitis C virus infection in hemodialysis patients. Am J Kidney Dis. 2005; 46: 290-300.
78. Pereira BJ, Milford EL, Kirkman RL, Quan S, Sayre KR, Johnson PJ, et al. Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs. N Engl J Med. 1992; 327: 910-915.
79. Guideline 1: Detection and evaluation of HCV in CKD. Kidney Int. 2008; 73: S10-S19.
80. Guideline 2: Treatment of HCV infection in patients with CKD. Kidney Int. 2008; 73: S20-S45.
81. Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis. 2003; 42: 631-657.
82. Teta D, Luscher BL, Gonvers JJ, Francioli P, Phan O, Burnier M. Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients. Nephrol Dial Transplant. 2005; 20: 991-993.
83. Russo MW, Ghalib R, Sigal S, Joshi V. Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant. 2006; 21: 437-443.
84. Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis. 2008; 51: 263-277.
85. dos Santos JP, Loureiro A, Cendoroglo Neto M, Pereira BJ. Impact of dialysis room and reuse strategies on the incidence of hepatitis C virus infection in haemodialysis units. Nephrol Dial Transplant. 1996; 11: 2017-2022.
86. Jadoul M, Cornu C, van Ypersele de Strihou C. Incidence and risk factors for hepatitis C seroconversion in hemodialysis: a prospective study. The UCL Collaborative Group. Kidney Int. 1993; 44: 1322-1326.
87. Jadoul M, Cornu C, van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group. Kidney Int. 1998; 53: 1022-1025.
88. Aucella F, Vigilante M, Valente GL, Stallone C. Systematic monitor disinfection is effective in limiting HCV spread in hemodialysis. Blood Purif. 2000; 18: 110-114.
89. Guideline 3: Preventing HCV transmission in hemodialysis units. Kidney Int. 2008; 73: S46-S52.
90. Perez G, Ortiz-Interian C, Lee H, de Medina M, Cerney M, Allain JP, et al. Human immunodeficiency virus and human T-cell leukemia virus type I in patients undergoing maintenance hemodialysis in Miami. Am J Kidney Dis. 1989; 14: 39-43.
91. Vigneau C, Guiard-Schmid JB, Tourret J, Flahault A, Rozenbaum W, Pialoux G, et al. The clinical characteristics of HIVinfected patients receiving dialysis in France between 1997 and 2002. Kidney Int. 2005; 67: 1509-1514.
92. Eggers PW, Kimmel PL. Is there an epidemic of HIV Infection in the US ESRD program? J Am Soc Nephrol. 2004; 15: 2477-2485.
93. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Volberding PA, O'Hare AM. Racial differences in end-stage renal disease rates in HIV infection versus diabetes. J Am Soc Nephrol. 2007; 18: 2968-2974.
94. Lucas GM, Lau B, Atta MG, Fine DM, Keruly J, Moore RD. Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. J Infect Dis. 2008; 197: 1548-1557.
95. D'Agati V, Appel GB. Renal pathology of human immunodeficiency virus infection. Semin Nephrol. 1998; 18: 406-421.
96. Vardinon N, Yust I, Katz O, Iaina A, Katzir Z, Modai D, et al. Anti-HIV indeterminate western blot in dialysis patients: a longterm follow-up. Am J Kidney Dis. 1999; 34: 146-149.
97. El Sayed NM, Gomatos PJ, Beck-Sague CM, Dietrich U, von Briesen H, Osmanov S, et al. Epidemic transmission of human immunodeficiency virus in renal dialysis centers in Egypt. J Infect Dis. 2000; 181: 91-97.
98. Velandia M, Fridkin SK, Cardenas V, Boshell J, Ramirez G, Bland L, et al. Transmission of HIV in dialysis centre. Lancet. 1995; 345: 1417-1422.
99. Henderson DK, Fahey BJ, Willy M, Schmitt JM, Carey K, Koziol DE, et al. Risk for occupational transmission of human immunodeficiency virus type 1 (HIV-1) associated with clinical exposures. A prospective evaluation. Ann Intern Med. 1990; 113: 740-746.
100. Bell DM. Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview. Am J Med. 1997; 102: 9-15.
101. Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med. 1997; 337: 1485-1490.
102. Smith DK, Grohskopf LA, Black RJ, Auerbach JD, Veronese F, Struble KA, et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep. 2005; 54: 1-20.
103. Panlilio AL, Cardo DM, Grohskopf LA, Heneine W, Ross CS. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep. 2005; 54: 1-17.
104. Curi MA, Pappas PJ, Silva MB, Jr., Patel S, Padberg FT, Jr., Jamil Z, et al, 2nd. Hemodialysis access: influence of the human immunodeficiency virus on patency and infection rates. J Vasc Surg. 1999; 29: 608-616.
105. Mitchell D, Krishnasami Z, Young CJ, Allon M. Arteriovenous access outcomes in haemodialysis patients with HIV infection. Nephrol Dial Transplant. 2007; 22: 465-470.
106. Mitchell D, Krishnasami Z, Allon M. Catheter-related bacteraemia in haemodialysis patients with HIV infection. Nephrol Dial Transplant. 2006; 21: 3185-3188.
107. Shrivastava D, Rao TK, Sinert R, Khurana E, Lundin AP, Friedman EA. The efficacy of erythropoietin in human immunodeficiency virus-infected end-stage renal disease patients treated by maintenance hemodialysis. Am J Kidney Dis. 1995; 25: 904-909.
108. Oberai PC, Dalal D, Zhang L, Wang C, Eustace J, Parekh RS. Incidence of atherosclerotic cardiovascular disease among HIV patients receiving dialysis. Am J Kidney Dis. 2006; 47: 848-855.
109. Ahuja TS, Borucki M, Grady J. Highly active antiretroviral therapy improves survival of HIV-infected hemodialysis patients. Am J Kidney Dis. 2000; 36: 574-580.
110. Ortiz C, Meneses R, Jaffe D, Fernandez JA, Perez G, Bourgoignie JJ. Outcome of patients with human immunodeficiency virus on maintenance hemodialysis. Kidney Int. 1988; 34: 248-253.
111. Perinbasekar S, Brod-Miller C, Pal S, Mattana J. Predictors of survival in HIV-infected patients on hemodialysis. Am J Nephrol. 1996; 16: 280-286.
112. Ahuja TS, Grady J, Khan S. Changing trends in the survival of dialysis patients with human immunodeficiency virus in the United States. J Am Soc Nephrol. 2002; 13: 1889-1893.
113. Tourret J, Tostivint I, du Montcel ST, Bragg-Gresham J, Karie S, Vigneau C, et al. Outcome and prognosis factors in HIVinfected hemodialysis patients. Clin J Am Soc Nephrol. 2006; 1: 1241-1247.
114. Hammer SM, Eron JJ, Jr., Reiss P, Schooley RT, Thompson MA, Walmsley S, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008; 300: 555-570.
115. Tourret J, Tostivint I, Tezenas Du Montcel S, Karie S, Launay-Vacher V, Vigneau C, et al. Antiretroviral drug dosing errors in HIV-infected patients undergoing hemodialysis. Clin Infect Dis. 2007; 45: 779-784.
116. Choi AI, Rodriguez RA, Bacchetti P, Volberding PA, Havlir D, Bertenthal D, et al. Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease. Clin Infect Dis. 2007; 45: 1633-1639.